Tag: MONOGRAPH

  • Lithium Orotate

    Lithium-orotate complex

    A lithium salt of orotic acid sold as a low-dose dietary supplement for mood and cognitive applications, distinct from prescription lithium carbonate.

    Abstract

    Lithium orotate is a salt of lithium with orotic acid (a pyrimidine biosynthesis intermediate). At supplement doses, lithium plasma concentrations are well below the therapeutic and toxic ranges of clinical lithium use. The pharmacology of low-dose lithium for mood and cognitive applications is debated; some epidemiological studies suggest reduced suicide rates and dementia incidence in regions with higher dietary lithium, but the magnitude is small and confounded.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Nicotine

    Nicotinic acetylcholine receptor agonist

    A pyridine alkaloid from tobacco (Nicotiana spp.) with broad nicotinic acetylcholine receptor agonist activity, studied at low doses for cognitive enhancement.

    Abstract

    Nicotine (CAS 54-11-5; molecular formula C10H14N2; molecular weight 162.23) is a pyridine alkaloid present principally in Nicotiana tabacum and other Solanaceae species. The compound is a potent agonist at nicotinic acetylcholine receptors (nAChRs) with affinity that varies by subunit composition: alpha4-beta2 nAChRs (high abundance in CNS) at high affinity, alpha7 nAChRs at moderate affinity, alpha3-containing autonomic nAChRs at moderate affinity. Low-dose nicotine has been studied extensively for cognitive enhancement (improved attention, working memory) in non-smokers; effect sizes are modest but consistent. Smoking cessation pharmacotherapy uses nicotine replacement (gum, patch, lozenge, inhaler, nasal spray) at doses sufficient to relieve withdrawal but lower than typical cigarette smoking exposure. The compound is highly addictive when delivered through rapid-onset routes (smoking, vaping); slower-onset routes (gum, patch) have lower abuse liability.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mianserin

    Tetracyclic alpha-2 adrenergic antagonist

    A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

    Abstract

    Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Quetiapine

    Atypical antipsychotic

    A dibenzothiazepine atypical antipsychotic with broad receptor binding; the active metabolite norquetiapine is a NET inhibitor contributing to antidepressant efficacy.

    Abstract

    Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol; CAS 111974-69-7; molecular formula C21H25N3O2S; molecular weight 383.51) is a dibenzothiazepine atypical antipsychotic developed at AstraZeneca and approved by the FDA in 1997 under the trade name Seroquel. The receptor profile is broad: D2 (Ki approximately 770 nM, the weakest of the antipsychotic class), 5-HT2A (Ki approximately 295 nM), H1 (Ki approximately 11 nM), alpha-1 (Ki approximately 22 nM), 5-HT1A partial agonism. The active metabolite norquetiapine (formed via CYP3A4) is a potent NET inhibitor (Ki approximately 35 nM) and a 5-HT2C antagonist, contributing to antidepressant efficacy and supporting the FDA-approved adjunctive use in major depressive disorder. Plasma half-life is 6 to 7 hours; metabolism is via CYP3A4. Approved for schizophrenia, bipolar I disorder (mania, depression, maintenance), and adjunctive in MDD. Off-label use as a hypnotic at 25 to 100 mg is widespread despite a poor efficacy-to-side-effect ratio for that indication. Used as a reference broad-spectrum atypical antipsychotic in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Hydroxyzine

    First-generation H1 antihistamine anxiolytic

    A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

    Abstract

    Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dutasteride

    Dual 5-alpha-reductase I/II inhibitor

    A 4-azasteroid dual 5-alpha-reductase inhibitor (types I and II); more complete DHT suppression than finasteride.

    Abstract

    Dutasteride ((5-alpha,17-beta)-N-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide; CAS 164656-23-9; molecular formula C27H30F6N2O2; molecular weight 528.53) is a 4-azasteroid dual 5-alpha-reductase inhibitor developed at GlaxoSmithKline and approved by the FDA in 2002 under the trade name Avodart. Distinct from finasteride by inhibition of both 5AR isozymes (type I Ki approximately 0.6 nM, type II Ki approximately 0.3 nM, both substantially more potent than finasteride at type II). Plasma half-life is approximately 5 weeks (the longest in the 5AR inhibitor class), reflecting tight tissue binding. Approved for benign prostatic hyperplasia; off-label use in androgenetic alopecia (often more effective than finasteride). The longer half-life means slower offset of effect on discontinuation but also slower washout for fertility planning. Sexual side effects parallel finasteride. Used as the canonical dual 5AR inhibitor in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dasatinib

    Tyrosine kinase inhibitor / senolytic

    A multi-target tyrosine kinase inhibitor approved for chronic myeloid leukemia; repurposed in senolytic combination therapy with quercetin (D+Q).

    Abstract

    Dasatinib (BMS-354825; CAS 302962-49-8; molecular formula C22H26ClN7O2S; molecular weight 488.01) is a multi-target tyrosine kinase inhibitor developed at Bristol-Myers Squibb and approved by the FDA in 2006 under the trade name Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. The senolytic application emerged from work by Kirkland and Tchkonia at Mayo Clinic (2015 onward) demonstrating that the combination of dasatinib (targeting senescent cells of mesenchymal origin) and quercetin (targeting senescent cells of epithelial origin) selectively eliminates senescent cells while sparing healthy cells. Plasma half-life is approximately 5 hours; metabolism is via CYP3A4. Used as the canonical senolytic small molecule with clinical translation.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cannabinol (CBN)

    Phytocannabinoid (THC degradation product)

    A phytocannabinoid produced by THC oxidation in aged cannabis; weakly intoxicating; widely marketed as a sleep aid despite limited clinical evidence.

    Abstract

    Cannabinol (CBN; CAS 521-35-7; molecular formula C21H26O2; molecular weight 310.43) is a phytocannabinoid formed primarily by oxidative degradation of THC; aged cannabis develops higher CBN concentrations. The compound retains weak CB1 partial agonist activity (approximately 10 percent of THC potency at CB1), producing mild psychoactive effects at high doses. CB2 affinity is comparable to or higher than CB1. Pharmacologically distinguished from THC by the aromatized A-ring, which reduces CB1 binding but preserves other interactions. Marketing claims position CBN as a sleep aid; clinical evidence for this is limited (one 1976 trial and small subsequent studies), and the sedation may largely reflect residual THC contamination in early CBN samples. Plasma kinetics parallel other cannabinoids. Used as a CB receptor partial agonist research compound; the sleep marketing claims await rigorous clinical validation.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Propofol

    GABA-A receptor positive allosteric modulator (intravenous anesthetic)

    An alkylphenol intravenous general anesthetic; the most widely used induction anesthetic and the agent in Michael Jackson’s death.

    Abstract

    Propofol (2,6-diisopropylphenol; CAS 2078-54-8; molecular formula C12H18O; molecular weight 178.27) is an alkylphenol intravenous general anesthetic developed at ICI (now AstraZeneca) and approved by the FDA in 1989 (Diprivan). The compound is a GABA-A receptor positive allosteric modulator at a unique propofol-binding site distinct from the benzodiazepine, barbiturate, and steroid sites; the result is enhanced GABA-mediated chloride conductance and pronounced CNS depression. Formulation is a 1 percent oil-in-water emulsion (the source of the milky appearance). Plasma half-life is biphasic: rapid distribution (2 to 4 minutes) and slower elimination (3 to 12 hours). Approved indications: induction and maintenance of general anesthesia, sedation in ICU. Misuse for amateur sedation is associated with the death of Michael Jackson (2009). Propofol infusion syndrome (rare) involves metabolic acidosis, rhabdomyolysis, and cardiac failure with prolonged high-dose use. Used as the canonical IV anesthetic in research and clinical practice.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Romosozumab

    Anti-sclerostin monoclonal antibody

    A humanized monoclonal antibody against sclerostin; a dual-action bone agent that increases formation and decreases resorption.

    Abstract

    Romosozumab (CAS 909395-70-6; humanized IgG2 monoclonal antibody against sclerostin; molecular weight approximately 145 kDa) is a humanized monoclonal antibody developed by Amgen and UCB and approved by the FDA in 2019 (Evenity). The compound binds sclerostin (a glycoprotein produced by osteocytes that inhibits Wnt signaling on osteoblasts), neutralizing its inhibitory effect on bone formation. Mechanism is dual-action: increased bone formation (Wnt pathway de-inhibition on osteoblasts) plus decreased bone resorption (reduced osteoclast differentiation), an unusual combination producing more rapid BMD gains than any other osteoporosis agent. Approved for postmenopausal osteoporosis at high fracture risk. The ARCH trial demonstrated superior fracture reduction versus alendronate. Cardiovascular safety signal (increased cardiovascular events versus alendronate in ARCH) led to a black-box warning; the compound is contraindicated in patients with recent myocardial infarction or stroke. Treatment duration is 12 months (loss of effect with longer treatment). Used as the canonical anti-sclerostin agent.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.